ICER to review peanut allergy therapies from Aimmune, DBV

The Institute for Clinical and Economic Review (ICER) will review peanut allergy therapies AR101 from Aimmune Therapeutics Inc. (NASDAQ:AIMT) and Viaskin Peanut from DBV

Read the full 242 word article

User Sign In